X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-10-15 | NATR | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% | S - Sale | $13.02 | -2,300 | 2,918,774 | 0% | -$29,946 | ||||||
| M | 2024-10-01 | NATR | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% | S - Sale | $13.33 | -10,895 | 2,921,074 | 0% | -$145,189 | |||||
2024-06-06 | NATR | Yates Bryant J | EVP, Pres, Europe | S - Sale | $15.30 | -3,068 | 98,852 | -3% | -$46,940 | ||||||
| M | 2023-11-29 | NATR | Norman Daniel C | EVP, Pres, Asia | S - Sale | $17.13 | -15,000 | 54,765 | -22% | -$256,960 | |||||
2023-11-21 | NATR | Brower Nathan G | EVP, GC | S - Sale | $17.31 | -3,999 | 43,760 | -8% | -$69,223 | ||||||
| D | 2023-08-29 | NATR | Yates Bryant J | EVP, Pres, Europe | S - Sale+OE | $16.77 | -15,000 | 94,150 | -14% | -$251,550 | |||||
| DM | 2023-08-25 | NATR | Norman Daniel C | EVP, Pres, Asia | S - Sale+OE | $16.40 | -12,236 | 69,765 | -15% | -$200,690 | |||||
| M | 2023-05-25 | NATR | Yates Bryant J | EVP, Pres, Europe | S - Sale | $11.63 | -9,468 | 95,703 | -9% | -$110,083 | |||||
| M | 2023-05-22 | NATR | Norman Daniel C | EVP, Pres, Asia | S - Sale | $11.18 | -15,470 | 71,318 | -18% | -$172,914 | |||||
| M | 2023-05-18 | NATR | Brower Nathan G | EVP, GC | S - Sale | $10.97 | -11,396 | 49,053 | -19% | -$124,969 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |